NCT05406817View on ClinicalTrials.gov

Study of Radiolabeled Revumenib in Adults With Acute Leukemia

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

August 5, 2022

Primary Completion Date

November 18, 2024

Study Completion Date

November 18, 2024

Conditions
Acute Leukemia
Interventions
DRUG

Revumenib

Initial radiolabeled revumenib will be administered as an oral solution. Capsules will be administered thereafter.

Trial Locations (1)

77030

MD Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
lead

Syndax Pharmaceuticals

INDUSTRY

NCT05406817 - Study of Radiolabeled Revumenib in Adults With Acute Leukemia | Biotech Hunter | Biotech Hunter